Literature DB >> 24335203

Pityriasis rosea in a hepatitis B-positive patient treated with pegylated interferon α2a: report of a case and review of the literature.

Francesco Drago1, Sanja Javor, Linda Bruzzone, Francesca Drago, Aurora Parodi, Antonino Picciotto.   

Abstract

Pityriasis rosea (PR) is an acute, self-limiting exanthematous disease caused by the endogenous reactivation of human herpesvirus (HHV)-6 and/or HHV-7 infection in conditions of altered immunity. In addition, many drugs have been incriminated as possible triggers of PR-like eruptions, characterized by clinical, morphological and histopathological features that differ from typical PR. Here, we report a case of PR in a patient with chronic hepatitis B, receiving pegylated interferon α2a (PEG-IFN-α2a). PR, arising after the second administration of the PEG-IFN-α2a, might be considered a clinical expression of the patient's altered immune condition as reported in the immune reconstitution inflammatory syndrome affecting patients with human immunodeficiency virus infection after high-dose antiretroviral therapy.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24335203     DOI: 10.1159/000356176

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Pityriasis rosea in a patient with retrovirus infection: a reply.

Authors:  Giulia Ciccarese; Aurora Parodi; Francesca Drago; Astrid Herzum; Francesco Drago
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

2.  Red Cell Distribution Width and Mean Platelet Volume in Patients With Pityriasis Rosea.

Authors:  Gunseli Sefika Pancar; Oznur Eyupoglu
Journal:  J Clin Med Res       Date:  2016-05-25

3.  Occult Hepatitis B Virus Infections (Often with Human Herpesvirus 7 Co-Infection) Detected in Pityriasis rosea Patients: A Pilot Study.

Authors:  Abhishek De; Subrata Roy; Soumi Sukla; Asad Ansari; Subhajit Biswas
Journal:  Indian J Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.494

4.  Pityriasis rosea following human papillomavirus vaccination.

Authors:  Francesco Drago; Giulia Ciccarese; Alfredo Rebora; Aurora Parodi
Journal:  Braz J Infect Dis       Date:  2014-12-17       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.